Stock Ratings / Health Care / XCUR / earnings

APRE (42) ACXP (39) FBLG (40) ALZN (47) ⌘ Pro Terminal →

Exicure Inc. (XCUR) Next Earnings Date & Expected ±12.5% Move

$0.93 -8.04% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Exicure Inc. (XCUR) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $6.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XCUR)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.12 Expected Swing

MODEL EARNINGS SETUP GAUGE

XCUR Quantitative Pre-Earnings Setup: 35/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (35/100)Model Risk Weight (65/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	-$4.9M	-$8.6M	52%
FY 2024	2024-12-31	$500.0K	-$9.7M	-$2.9M	52%
FY 2023	2023-12-31	$0	-$16.9M	-$10.4M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XCUR)

✓Walkthrough of XCUR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

XCUR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -72.32%⚡ TESTING RESISTANCE

2026-10-30O $0.94H $1.06L $0.93C $0.93VOL 29.6K

RES: $1.09SUP: $0.89SMA50: $1.19SMA200: $2.72

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XCUR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XCUR Butterfly Map → + Track XCUR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on XCUR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XCUR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for XCUR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XCUR)

Health Care Rank #831 of 1016 ⚔️ APRE vs XCUR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (XCUR vs. APRE, ACXP, FBLG, ALZN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Exicure Inc. (XCUR) ranks #831 by composite RQD confidence (35/100, grade D-) and #927 by equity capitalization ($6.1M). Within this direct 5-issuer industry benchmark cohort, XCUR leads on earnings valuation at N/A trailing P/E, while XCUR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ALZN currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with XCUR at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
XCUR ACTIVE Exicure Inc.	D-	35/100	—	—	-35.0%	-8.04%	$6.1M	Benchmark Subject
APRE Aprea Therapeutics Inc.	D-	42/100	—	—	-35.0%	-8.22%	$6.2M	/apre-vs-xcur →
ACXP Acurx Pharmaceuticals Inc.	D-	39/100	—	—	-35.0%	0.00%	$5.9M	/acxp-vs-xcur →
FBLG FibroBiologics Inc.	D-	40/100	—	—	-35.0%	-3.99%	$6.3M	/fblg-vs-xcur →
ALZN Alzamend Neuro Inc.	D	47/100	—	—	-35.0%	+2.52%	$5.9M	/alzn-vs-xcur →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001698530

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Exicure Inc. (XCUR) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $500.0K ) , GAAP net income of -$4.9M, operating cash flow of -$8.6M, and free cash flow of -$8.6M (-194.0% YoY). On the balance sheet, XCUR closed FY2025 with $14.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$4.9M	-$8.6M	-$8.6M	$14.0M	—
FY2024 (FY)	2024-12-31	$500.0K	-$9.7M	-$2.9M	-$2.9M	$15.1M	—
FY2023 (FY)	2023-12-31	$0	-$16.9M	-$10.4M	-$10.4M	—	—

3. XCUR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XCUR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Exicure Inc. (NASDAQ: XCUR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.93 (-8.04% 1D, market cap $6.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, XCUR ranks #831 in composite RQD confidence.

How does XCUR compare to APRE and ACXP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XCUR carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, APRE (Aprea Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $6.2M) and ACXP (Acurx Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $5.9M). Among the 5-stock peer group, XCUR leads on earnings multiple (N/A) while XCUR leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for XCUR?

Per XCUR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001698530), Exicure Inc. generated $0 in revenue (-100.0% YoY), -$4.9M in net income, and -$8.6M in free cash flow against $14.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is XCUR trading relative to its 50-day, 200-day, and 52-week technical levels?

XCUR last traded at $0.93 (-8.04% on volume of 41,443 shares), positioning the stock -21.85% below its 50-day simple moving average ($1.19) and -65.81% below its 200-day simple moving average ($2.72). Across its 52-week range of $0.88 to $9.48, XCUR sits at the 0.6% percentile with a 14-day RSI of 43.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.05).